Revolution Medicines Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Revolution Medicines şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.9%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.9%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Calculating The Intrinsic Value Of Revolution Medicines, Inc. (NASDAQ:RVMD)

Sep 28

This Is Why Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Looks Appropriate

Jun 15

Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation

Aug 09

Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates

May 13

We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth

Apr 02

We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely

Dec 20

We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate

Sep 15

Revolution Medicines promotes Jack Anders to CFO

Sep 02

New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)

Aug 10

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: RVMD şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: RVMD şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Revolution Medicines Piyasaya Karşı Temettü Getirisi

RVMD temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (RVMD)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (RVMD) (3 yıla kadar)	0%

Önemli Temettü: RVMD şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, RVMD şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: RVMD şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: RVMD herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Revolution Medicines Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

President of Research & Development exercised options and sold US$909k worth of stock

CEO, President & Chairman exercised options and sold US$3.1m worth of stock

CEO, President & Chairman recently sold US$550k worth of stock

Consensus revenue estimates decrease by 57%

CEO, President & Chairman notifies of intention to sell stock

Revolution Medicines, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Chief Operating Officer notifies of intention to sell stock

CEO, President & Chairman notifies of intention to sell stock

Calculating The Intrinsic Value Of Revolution Medicines, Inc. (NASDAQ:RVMD)

President of Research & Development notifies of intention to sell stock

President of Research & Development notifies of intention to sell stock

Consensus revenue estimates fall by 76%

First half 2024 earnings released: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)

Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

CEO, President & Chairman notifies of intention to sell stock

Revolution Medicines, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Revolution Medicines, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024

CEO, President & Chairman notifies of intention to sell stock

Revolution Medicines, Inc. Announces Publication Demonstrating Robust Anti-Tumor Activity of Ras(On) Inhibitors in Preclinical Models of Refractory Kras-Mutated Non-Small Cell Lung Cancer

Now 31% overvalued after recent price rise

CEO, President & Chairman notifies of intention to sell stock

This Is Why Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Looks Appropriate

Revolution Medicines: On Hold Pending A Lower Entry Point

Consensus revenue estimates decrease by 52%, EPS upgraded

Price target increased by 7.8% to US$44.82

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)

Chief Financial Officer notifies of intention to sell stock

Revolution Medicines, Inc. to Report Q1, 2024 Results on May 08, 2024

Revolution Medicines, Inc., Annual General Meeting, Jun 20, 2024

Price target increased by 7.1% to US$41.58

Revolution Medicines: An Expensive Shot At A Massive Market Opportunity

Price target increased by 7.7% to US$39.83

Chief Operating Officer notifies of intention to sell stock

Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $124.825544 million.

Consensus revenue estimates fall by 92%

Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Revolution Medicines, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Revolution Medicines Is Hard To Understand

President of Research & Development notifies of intention to sell stock

New major risk - Shareholder dilution

Price target decreased by 7.0% to US$34.14

Consensus revenue estimates decrease by 31%

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Third quarter 2023 earnings released: US$0.99 loss per share (vs US$0.87 loss in 3Q 2022)

Revolution Medicines, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Revolution Medicines, Inc. Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

New major risk - Revenue and earnings growth

Price target increased by 7.9% to US$37.14

Revolution Medicines, Inc. Provides Pipeline Updates

New minor risk - Share price stability

President of Research & Development notifies of intention to sell stock

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

Revolution Medicines, Inc. Resigns Eric T. Schmidt as Board of Directors

CEO, President & Chairman notifies of intention to sell stock

Consensus revenue estimates increase by 15%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2023

Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation

Revolution Medicines, Inc. to Report Q2, 2023 Results on Aug 08, 2023

President of Research & Development notifies of intention to sell stock

Revolution Medicines, Inc. (NasdaqGS:RVMD) entered into a definitive agreement to acquire EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Price target increased by 9.4% to US$34.29

Revolution Medicines, Inc.(NasdaqGS:RVMD) dropped from Russell Small Cap Comp Value Index

Consensus revenue estimates decrease by 25%

Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Revolution Medicines, Inc. Announces Executives Appointment

We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth

Consensus revenue estimates fall by 34%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.0% to US$32.22